相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial
A. Poveda et al.
ANNALS OF ONCOLOGY (2011)
Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer
Christopher S. Bryant et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2011)
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer
Peter G. Rose et al.
GYNECOLOGIC ONCOLOGY (2011)
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial
Florence Joly et al.
GYNECOLOGIC ONCOLOGY (2011)
Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer New Data From the Randomized OVA-301 Study
Nicoletta Colombo
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
WHOLE ABDOMINOPELVIC RADIOTHERAPY USING INTENSITY-MODULATED ARC THERAPY IN THE PALLIATIVE TREATMENT OF CHEMOTHERAPY-RESISTANT OVARIAN CANCER WITH BULKY PERITONEAL DISEASE: A SINGLE-INSTITUTION EXPERIENCE
Gert De Meerleer et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
Jalid Sehouli et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
Natalia Issaeva et al.
CANCER RESEARCH (2010)
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
Ponnari Gottipati et al.
CANCER RESEARCH (2010)
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2010)
A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin
Mansoor Raza Mirza et al.
GYNECOLOGIC ONCOLOGY (2010)
Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?
Edward J. Tanner et al.
GYNECOLOGIC ONCOLOGY (2010)
Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: An updated series
K. K. Shih et al.
GYNECOLOGIC ONCOLOGY (2010)
Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
Ignace Vergote et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Koen De Geest et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation
Shauna L. Hillman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough?
Stephen A. Cannistra
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Weekly paclitaxel in the treatment of recurrent ovarian cancer
Richard D. Baird et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Making the best of PARP inhibitors in ovarian cancer
Susana Banerjee et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
H. Oksefjell et al.
ANNALS OF ONCOLOGY (2009)
Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis
P. Harter et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Hypersensitivity reactions to antineoplastic agents: an overview
Ekaterini Syrigou et al.
ANTI-CANCER DRUGS (2009)
Antiangiogenic drugs in ovarian cancer
G. C. Kumaran et al.
BRITISH JOURNAL OF CANCER (2009)
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
R. Sharma et al.
BRITISH JOURNAL OF CANCER (2009)
Surveillance of patients after initial treatment of ovarian cancer
Angiolo Gadducci et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
Werner Meier et al.
GYNECOLOGIC ONCOLOGY (2009)
The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project
M. J. Fulham et al.
GYNECOLOGIC ONCOLOGY (2009)
Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
Robert E. Bristow et al.
GYNECOLOGIC ONCOLOGY (2009)
Symptom Control in Patients With Recurrent Ovarian Cancer Measuring the Benefit of Palliative Chemotherapy in Women With Platinum Refractory/Resistant Ovarian Cancer
Michael Friedlander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Epithelial Ovarian Cancer Role of Pegylated Liposomal Doxorubicin in Prolonging the Platinum-Free Interval and Cancer Antigen 125 Trends During Treatment
J. S. Tanguay et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer? A Retrospective Italian Multicentric Study
Angiolo Gadducci et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
What Is the Benefit of Bevacizumab Combined with Chemotherapy in Patients with Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Malignancies?
X. Cheng et al.
JOURNAL OF CHEMOTHERAPY (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
David S. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of fulvestrant in the treatment of recurrent ovarian carcinoma
S. G. Thomas et al.
GYNECOLOGIC ONCOLOGY (2008)
The role of regular physical examination in the detection of ovarian cancer recurrence
K. K. L. Chan et al.
GYNECOLOGIC ONCOLOGY (2008)
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer
J. D. Wright et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
Ursula A. Matulonis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: Results of a phase III study of the North-Eastern German Society of Gynecological Oncology ovarian cancer study group
Jalid Sehouli et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
Gabriella Ferrandina et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Late Congestive Heart Failure After Hematopoietic Cell Transplantation
Saro H. Armenian et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study
Dominique Koensgen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Aromatase inhibitors in gynecologic cancers
Carolyn Krasner
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer
Melissa M. Thrall et al.
GYNECOLOGIC ONCOLOGY (2007)
Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer
H. G. Strauss et al.
GYNECOLOGIC ONCOLOGY (2007)
Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma
Stephen J. Tebes et al.
GYNECOLOGIC ONCOLOGY (2007)
Surgery in recurrent ovarian cancer:: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
Philipp Harter et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Follow-up of ovarian and primary physical examination in patients with peritoneal carcinoma: The value of pretreatment elevated CA125 levels
Joseph Menczer et al.
GYNECOLOGIC ONCOLOGY (2006)
Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer
E. Choan et al.
GYNECOLOGIC ONCOLOGY (2006)
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: Standard protocol effective in 57 patients for 255 courses
CW Lee et al.
GYNECOLOGIC ONCOLOGY (2005)
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic oncology group study
RJ Schilder et al.
CLINICAL CANCER RESEARCH (2005)
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma:: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study
AJ González-Martín et al.
ANNALS OF ONCOLOGY (2005)
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
C Sessa et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance
HT See et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation
JL Wilder et al.
GYNECOLOGIC ONCOLOGY (2003)
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer
G D'Agostino et al.
GYNECOLOGIC ONCOLOGY (2003)
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2003)
No rules without exception: Long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer
L Paskeviciute et al.
GYNECOLOGIC ONCOLOGY (2002)
Peritoneal metastases: Detection with spiral CT in patients with ovarian cancer
FV Coakley et al.
RADIOLOGY (2002)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
M Colleoni et al.
ANNALS OF ONCOLOGY (2002)
Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma
C Scarabelli et al.
GYNECOLOGIC ONCOLOGY (2001)
Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum
S Firat et al.
GYNECOLOGIC ONCOLOGY (2001)
Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer
A Gadducci et al.
GYNECOLOGIC ONCOLOGY (2000)
Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy
KM Zanotti et al.
GYNECOLOGIC ONCOLOGY (2000)
分享论文
